10243-IMT-3 LONG-TERM OUTCOME OF A COCKTAIL WILMS' TUMOR 1 (WT1) VACCINATION USING TWO HLA CLASS I PEPTIDES AND ONE CLASS II PEPTIDE AGAINST RECURRENT MALIGNANT GLIOMAS

Naoki Kagawa, Yusuke Oji, Ryuichi Hirayama, Noriyuki Kijima, Yoshihiro Oka, Haruo Sugiyama, Haruhiko Kishima · 2023

Read 10243-IMT-3 LONG-TERM OUTCOME OF A COCKTAIL WILMS' TUMOR 1 (WT1) VACCINATION USING TWO HLA CLASS I PEPTIDES AND ONE CLASS II PEPTIDE AGAINST RECURRENT MALIGNANT GLIOMAS by Naoki Kagawa, Yusuke Oji, Ryuichi Hirayama, Noriyuki Kijima, Yoshihiro Oka, Haruo Sugiyama, Haruhiko Kishima (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10710615.txt.

Description

Naoki Kagawa and co-authors report long-term results of a peptide vaccine against recurrent brain tumors, in a 2023 paper. The vaccine targets Wilms' tumor 1, a protein common in malignant gliomas. Earlier trials of single-peptide versions proved safe and somewhat effective; this cocktail mixes three peptides to rally both killer and helper arms of immunity.

Twenty-three patients with recurrent tumors, positive for the target and for matching tissue types, received seven skin injections over three months. Fifteen had glioblastomas, eight anaplastic astrocytomas; average age was about forty-nine. The team tracked skin reactions and antibody rises as stand-ins for immune response, alongside survival. The long follow-up judges whether the broader vaccine's promise holds beyond the trial's first reports.

Catalog record

CREATORNaoki Kagawa, Yusuke Oji, Ryuichi Hirayama, Noriyuki Kijima, Yoshihiro Oka, Haruo Sugiyama, Haruhiko Kishima
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10710615

Browse the full library · About the Tower of Babel